Cancer active targeting by nanoparticles: a comprehensive review of literature
Cancer is one of the leading causes of death, and thus, the scientific community has but great efforts to improve cancer management. Among the major challenges in cancer management is development of agents that can be used for early diagnosis and effective therapy. Conventional cancer management frequently lacks accurate tools for detection of early tumors and has an associated risk of serious side effects of chemotherapeutics. The need to optimize therapeutic ratio as the difference with which a treatment affects cancer cells versus healthy tissues lead to idea that it is needful to have a treatment that could act a the “magic bullet”—recognize cancer cells only. Nanoparticle platforms offer a variety of potentially efficient solutions for development of targeted agents that can be exploited for cancer diagnosis and treatment. There are two ways by which targeting of nanoparticles can be achieved, namely passive and active targeting. Passive targeting allows for the efficient localization of nanoparticles within the tumor microenvironment. Active targeting facilitates the active uptake of nanoparticles by the tumor cells themselves.
Relevant English electronic databases and scientifically published original articles and reviews were systematically searched for the purpose of this review.
In this report, we present a comprehensive review of literatures focusing on the active targeting of nanoparticles to cancer cells, including antibody and antibody fragment-based targeting, antigen-based targeting, aptamer-based targeting, as well as ligand-based targeting.
To date, the optimum targeting strategy has not yet been announced, each has its own advantages and disadvantages even though a number of them have found their way for clinical application. Perhaps, a combination of strategies can be employed to improve the precision of drug delivery, paving the way for a more effective personalized therapy.
KeywordsCancer Active targeting Nanoparticles
- Anabousi S, Bakowsky U, Schneider M, Huwer H, Lehr CM, Ehrhardt C (2006) In vitro assessment of transferrin-conjugated liposomes as drug delivery systems for inhalation therapy of lung cancer. Eur J Pharm Sci Off J Eur Fed Pharm Sci 29(5):367–374Google Scholar
- Bouras A, Kaluzova M, Hadjipanayis CG (2012) 192 Epidermal growth factor receptor antibody-conjugated iron-oxide nanoparticles: therapeutic targeting and radiosensitivity enhancement of glioblastoma. Neurosurgery 71(2):E574–E575Google Scholar
- Chattopadhyay N, Fonge H, Cai Z, Scollard D, Lechtman E, Done SJ et al (2012) Role of antibody-mediated tumor targeting and route of administration in nanoparticle tumor accumulation in vivo. Mol Pharm 9(8):2168–2179Google Scholar
- Chiu TC, Huang CC (2009) Aptamer-functionalized nano-biosensors. Sensors (Basel) 9(12):10356–10388Google Scholar
- Corbin IR, Ng KK, Ding L, Jurisicova A, Zheng G (2012) Near-infrared fluorescent imaging of metastatic ovarian cancer using folate receptor-targeted high-density lipoprotein nanocarriers. Nanomedicine (Lond) 8(6):875–890Google Scholar
- Day ES, Bickford LR, Slater JH, Riggall NS, Drezek RA, West JL (2010) Antibody-conjugated gold–gold sulfide nanoparticles as multifunctional agents for imaging and therapy of breast cancer. Int J Nanomed 5:445–454Google Scholar
- Deepagan VG, Sarmento B, Menon D, Nascimento A, Jayasree A, Sreeranganathan M et al (2012) In vitro targeted imaging and delivery of camptothecin using cetuximab-conjugated multifunctional PLGA-ZnS nanoparticles. Nanomedicine (Lond) 7(4):507–519Google Scholar
- Gao X, Luo Y, Wang Y, Pang J, Liao C, Lu H et al (2012) Prostate stem cell antigen-targeted nanoparticles with dual functional properties: in vivo imaging and cancer chemotherapy. Int J Nanomed 7:4037–4051Google Scholar
- Harding J, Burtness B (2005) Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. Drugs Today (Barc) 41(2):107–127Google Scholar
- Huang YF, Lin YW, Lin ZH, Chang HT (2009) Aptamer-modified gold nanoparticles for targeting breast cancer cells through light scattering. J Nanopart Res 11:775–783Google Scholar
- Li N, Larson T, Nguyen HH, Sokolov KV, Ellington AD (2010) Directed evolution of gold nanoparticle delivery to cells. Chem Commun (Camb) 46(3):392–394Google Scholar
- Liu D, Chen C, Hu G, Mei Q, Qiu H, Long G (2011) Specific targeting of nasopharyngeal carcinoma cell line CNE1 by C225-conjugated ultrasmall superparamagnetic iron oxide particles with magnetic resonance imaging. Acta Biochim Biophys Sin (Shanghai) 43(4):301–306Google Scholar
- Low PS, Kularatne SA (2009) Folate-targeted therapeutic and imaging agents for cancer. Current Opin Chem Biol 13(3):256–262Google Scholar
- Pulkkinen M, Pikkarainen J, Wirth T, Tarvainen T, Haapa-aho V, Korhonen H et al (2008) Three-step tumor targeting of paclitaxel using biotinylated PLA-PEG nanoparticles and avidin-biotin technology: formulation development and in vitro anticancer activity. Eur J Pharm Biopharm 70(1):66–74PubMedGoogle Scholar
- Sugano M, Egilmez NK, Yokota SJ, Chen FA, Harding J, Huang SK et al (2000) Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice. Cancer Res 60(24):6942–6949PubMedGoogle Scholar
- Taylor RM, Sillerud LO (2012) Paclitaxel-loaded iron platinum stealth immunomicelles are potent MRI imaging agents that prevent prostate cancer growth in a PSMA-dependent manner. Int J Nanomed 7:4341–4352Google Scholar
- Wang H, Zheng L, Peng C, Shen M, Shi X, Zhang G (2013) Folic acid-modified dendrimer-entrapped gold nanoparticles as nanoprobes for targeted CT imaging of human lung adenocarcinoma. Biomaterials 34(2):470–480Google Scholar
- Wu J, Lu Y, Lee A, Pan X, Yang X, Zhao X et al (2007) Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil. J Pharm Pharm Sci Publ Can Soc Pharm Sci (Societe canadienne des sciences pharmaceutiques) 10(3):350–357Google Scholar
- Yang HM, Park CW, Woo MA, Kim MI, Jo YM, Park HG et al (2010) HER2/neu antibody conjugated poly(amino acid)-coated iron oxide nanoparticles for breast cancer MR imaging. Biomacromolecules 11(11):2866–2872Google Scholar
- Zhao N, Bagaria HG, Wong MS, Zu Y (2011) A nanocomplex that is both tumor cell-selective and cancer gene-specific for anaplastic large cell lymphoma. J Nanobiotechnol 9:2Google Scholar